|
Volumn 3, Issue 5, 2002, Pages 625-628
|
Class benefits of AT1 antagonists in Type 2 diabetes with nephropathy
|
Author keywords
AT1 antagonists; Irbesartan; Losartan; Type 2 diabetes
|
Indexed keywords
AMLODIPINE;
ANGIOTENSIN 2 RECEPTOR ANTAGONIST;
BRADYKININ B1 RECEPTOR;
CREATININE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
IRBESARTAN;
LOSARTAN;
PLACEBO;
RAMIPRIL;
ARTICLE;
BLOOD PRESSURE REGULATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CREATININE BLOOD LEVEL;
DEATH;
DIABETIC NEPHROPATHY;
DIABETIC NEUROPATHY;
DRUG EFFECT;
DRUG MECHANISM;
HUMAN;
HYPERKALEMIA;
KIDNEY FAILURE;
MORTALITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
OUTCOMES RESEARCH;
PATIENT COMPLIANCE;
RISK ASSESSMENT;
ANTIHYPERTENSIVE AGENTS;
BIPHENYL COMPOUNDS;
CLINICAL TRIALS;
DIABETES MELLITUS, TYPE 1;
DIABETIC NEPHROPATHIES;
EXPERT TESTIMONY;
HUMANS;
KIDNEY FAILURE, CHRONIC;
LOSARTAN;
MIDDLE AGED;
RECEPTOR, ANGIOTENSIN, TYPE 1;
RECEPTORS, ANGIOTENSIN;
TETRAZOLES;
|
EID: 0036091699
PISSN: 14656566
EISSN: None
Source Type: Journal
DOI: 10.1517/14656566.3.5.625 Document Type: Article |
Times cited : (5)
|
References (16)
|